Related Experiment Videos
Interferon-beta treatment of metastatic prostate cancer
Abstract:
A limited clinical trial of Interferon-beta (Human Fibroblast Interferon) in the treatment of advanced, hormone-refractory prostate cancer was conducted by the National Prostate Cancer Project (NPCP Protocol 2100). Sixteen patients with metastatic prostate cancer who had failed prior hormone therapy were entered into the study. Treatment consisted of 6 X 10(6) units of Interferon-beta intravenously three times per week for 12 weeks. Chills and fever were seen in ten of the 16 patients (62.5%), and mild hematologic toxicity occurred in four patients. No complete or partial responses were observed. Three patients had stable disease by NPCP criteria for a mean duration of 6.3 months. Progression of disease was seen in 13 of the 16 patients, eight of whom progressed during therapy. The results of this study suggest that Interferon-beta has limited efficacy in the treatment of advanced, hormone-refractory prostate cancer.
Insights
Interferon-beta showed limited efficacy in treating advanced, hormone-refractory prostate cancer. The clinical trial found no complete or partial responses, with most patients experiencing disease progression despite treatment.
Area of Science:
- Oncology
- Immunology
Background:
- Advanced prostate cancer often becomes hormone-refractory, necessitating alternative treatments.
- Interferon-beta is an immunomodulatory agent explored for various cancers.
Purpose of the Study:
- To evaluate the efficacy and safety of Interferon-beta in patients with advanced, hormone-refractory prostate cancer.
Main Methods:
- A National Prostate Cancer Project (NPCP) clinical trial (Protocol 2100) enrolled 16 patients.
- Patients received 6 x 10(6) units of Interferon-beta intravenously thrice weekly for 12 weeks.
Main Results:
- No complete or partial responses were observed in any patient.
- Three patients (18.75%) achieved stable disease for a mean of 6.3 months.
- Thirteen patients (81.25%) experienced disease progression, with eight progressing during treatment.
- Common side effects included chills and fever (62.5%) and mild hematologic toxicity (25%).
Conclusions:
- Interferon-beta demonstrates limited clinical efficacy as a monotherapy for advanced, hormone-refractory prostate cancer.
- The observed toxicity profile suggests a need for further investigation into its role in prostate cancer treatment.